Vistagen Therapeutics, Inc. VTGN 深 沪
已收盘 10-30 16:00:00 美东时间
0.1683
-0.002
-1.41%
华盛通- 最 高0.1726
- 今 开0.172
- 成交量 59.17万股
- 最 低 0.1653
- 昨 收 0.1707
- 总市值 746.86万
- 52周最高 5.14
- 市盈率 静 --
- 换手率 1.33%
- 52周最低 0.1653
- 委 比 26.74%
- 总股本 4437.69万
- 历史最高 495.00
- 量 比 0.73
- 振 幅 4.28%
- 历史最低 0.1653
- 每 手 1
- 风险率 1.30%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多VistaGen Therapeutics Announces Significant Workforce Restructuring Initiative
The latest announcement is out from VistaGen Therapeutics ( ($VTGN) ). On Octob...
10-31 05:49
VistaGen Updates Strategy for Pherine-Based CNS Therapies
The latest announcement is out from VistaGen Therapeutics ( ($VTGN) ). On Septe...
09-25 21:49
Penny Stock Vistagen Analyst Highlights Caution after Anxiety Data
Vistagen Inc. (NASDAQ:VTGN) surged on Wednesday after preliminary findings from the open-label extension portion of its PALISADE-4 Phase 3 trial evaluating intranasal fasedienol for acute social anxiety disorder. The company’s phase 3 PALISADE-4 trial of intranasal fasedienol for the acute treatment...
09-23 21:25
Why Worthington Enterprises Shares Are Trading Higher By Around 16%; Here Are 20 Stocks Moving Premarket
Shares of Worthington Enterprises, Inc (NYSE:WOR) rose sharply in pre-market trading after the company reported better-than-expected first-quarter financial results. Worthington reported quarterly earnings of 82 cents per share, which beat the analyst consensus estimate of 75 cents per share. The co...
09-23 16:27
VistaGen Reports Positive Long-Term Fasedienol Anxiety Data
The latest announcement is out from VistaGen Therapeutics ( ($VTGN) ). On Septe...
09-23 04:40
VistaGen Therapeutics Q1 EPS $(0.30) Beats $(0.36) Estimate, Sales $1.476M Beat $250.000K Estimate
VistaGen Therapeutics (NASDAQ:VTGN) reported quarterly losses of $(0.30) per share which beat the analyst consensus estimate of $(0.36) by 16.67 percent. This is a 36.17 percent increase over losses of $(0.47) per share from the same period last year. The company reported quarterly sales of $1.476 m...
08-14 20:50
VistaGen reports Phase 2 fasedienol trial topline results
VistaGen Therapeutics ( ($VTGN) ) has shared an announcement. On August 6, 2026...
08-07 05:36
Stifel Nicolaus Remains a Hold on VistaGen Therapeutics (VTGN)
In a report released today, Paul Matteis from Stifel Nicolaus maintained a Hold...
07-06 13:55
Penny Stock Vistagen Keeps Regulatory Plans Alive Despite Anxiety Study Miss
Vistagen Inc. (NASDAQ:VTGN) on Monday reported that its Phase 3 PALISADE-4 trial of intranasal fasedienol for the acute treatment of social anxiety disorder did not meet its primary endpoint in the overall study population. However, the company identified a statistically significant benefit in a pos...
07-01 01:35
VistaGen Therapeutics Q4 EPS $(0.37) Misses $(0.30) Estimate, Sales $465.000K Beat $320.000K Estimate
VistaGen Therapeutics (NASDAQ:VTGN) reported quarterly losses of $(0.37) per share which missed the analyst consensus estimate of $(0.30) by 23.33 percent. This is a 15.91 percent increase over losses of $(0.44) per share from the same period last year. The company reported quarterly sales of $465.0...
06-16 05:18
